소외열대질환 치료 시장 분석과 예측 : 유형별, 제품 유형별, 서비스별, 기술별, 용도별, 형태별, 도입 형태별, 최종 사용자별, 솔루션별, 제공 형태별(-2035년)

Neglected Tropical Disease Treatment Market is anticipated to expand from $4.64 billion in 2024 to $7.24 billion by 2034, growing at a CAGR of approximately 4.5%. The Neglected Tropical Disease Treatment Market encompasses therapies and interventions targeting diseases prevalent in tropical regions, often affecting impoverished communities. This market includes pharmaceuticals, vaccines, and vector control solutions aimed at diseases such as dengue, leishmaniasis, and Chagas disease. Increasing global health initiatives and funding are driving advancements in treatment accessibility and innovation, addressing both prevention and eradication efforts, while emphasizing sustainable healthcare solutions in underserved regions.

The Neglected Tropical Disease Treatment Market is evolving, driven by increased awareness and advancements in healthcare solutions. The pharmaceutical segment is the top-performing sector, with antiparasitic drugs leading due to their efficacy in treating a range of diseases. Vaccines are emerging as a promising sub-segment, showing potential for significant growth as research progresses. Diagnostic tools, particularly rapid diagnostic tests, are gaining traction as the second-highest performing segment. They offer quick and accurate disease detection, crucial in resource-limited settings. Innovative drug delivery systems are also contributing to market dynamics, enhancing treatment adherence and efficacy. The role of public-private partnerships is pivotal, fostering research and development initiatives. Investments in biotechnology and genomic research are expected to drive future advancements, paving the way for novel therapeutics. The focus on sustainable healthcare solutions is increasing, with an emphasis on affordability and accessibility, addressing the needs of underserved populations worldwide.

Market Snapshot:

The Neglected Tropical Disease Treatment Market is experiencing dynamic shifts in market share, pricing, and product innovation. Established pharmaceutical companies and emerging biotech firms are actively launching new treatments, driving competition. Pricing strategies are evolving, influenced by the need for affordable solutions in low-income regions. The market is characterized by a diverse range of therapeutic products, with a focus on both traditional and novel treatment modalities. This landscape is fostering a competitive environment where companies are striving to enhance their market presence through strategic partnerships and collaborations. Competition within the market is intense, with key players benchmarking their offerings against rivals to gain a competitive edge. Regulatory influences play a crucial role, with stringent guidelines shaping product development and approval processes. The market is influenced by global health initiatives and funding from international organizations, which support research and development efforts. As companies navigate regulatory landscapes, they are also focusing on expanding access to treatment, particularly in underserved regions. The market is poised for growth, driven by a combination of innovation and strategic regulatory compliance.

Geographical Overview:

The Neglected Tropical Disease (NTD) Treatment Market is witnessing varied growth across different regions, each showcasing unique opportunities. Africa remains a focal point, driven by high disease prevalence and increased governmental and non-governmental interventions. Countries like Nigeria and the Democratic Republic of the Congo are emerging as key players due to extensive healthcare initiatives. In Asia Pacific, India and Indonesia are notable for their robust public health campaigns and expanding pharmaceutical sectors, which are critical in addressing NTDs. The region's economic growth and healthcare investments are propelling market expansion. Latin America, led by Brazil and Mexico, is experiencing growth through increased awareness and public health policies aimed at combating NTDs. The Middle East shows potential, particularly in countries like Saudi Arabia, where healthcare modernization is a priority. These regions present lucrative opportunities for stakeholders aiming to invest in innovative treatments and infrastructure to tackle NTDs effectively.

Key Trends and Drivers:

The Neglected Tropical Disease Treatment Market is experiencing growth due to increased awareness and governmental initiatives. Key trends include the rising investment in research and development, which is fostering innovation in treatment options. Pharmaceutical companies are collaborating with non-governmental organizations to enhance accessibility and affordability of treatments. There is also a growing emphasis on developing vaccines, contributing to the market's expansion. Drivers for this market include the rising prevalence of neglected tropical diseases in developing regions, prompting a demand for effective treatments. Increased funding from international health organizations is supporting the development of new therapies. Public-private partnerships are playing a crucial role in accelerating drug development processes. Furthermore, technological advancements in biotechnology are enabling more efficient drug discovery and development. Opportunities are emerging in the form of expanding healthcare infrastructure in emerging economies, which is enhancing the distribution and accessibility of treatments. Companies focusing on cost-effective and scalable solutions are well-positioned to capture market share. Additionally, the increasing focus on preventive care and early intervention is likely to drive demand for diagnostic tools and vaccines, ensuring sustained market growth.

Restraints and Challenges:

The neglected tropical disease treatment market encounters significant restraints and challenges. A primary challenge is inadequate funding, which hampers research and development efforts. This financial shortfall limits the availability of innovative treatments and hinders market expansion. Additionally, there is a scarcity of skilled healthcare professionals in affected regions, which affects the delivery and effectiveness of treatments. Furthermore, the complexity of disease diagnosis in resource-limited settings poses a significant barrier to timely and accurate treatment. Regulatory hurdles and lengthy approval processes delay the introduction of new therapies, further constraining market growth. Lastly, socio-economic factors, such as poverty and lack of education, exacerbate the difficulty in accessing and adhering to treatment regimens. These challenges collectively impede the market's potential to address the needs of those suffering from neglected tropical diseases.

Key Players:

Eisai Co Ltd, Sanofi Pasteur, Gilead Sciences, Boehringer Ingelheim, Fujifilm Holdings Corporation, Merck KGaA, Johnson & Johnson, Novartis AG, Pfizer Inc, GlaxoSmithKline plc, AbbVie Inc, Bayer AG, Roche Holding AG, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Takeda Pharmaceutical Company, Amgen Inc, Biocon Limited, Cipla Limited

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by Form
• 2.7 Key Market Highlights by Deployment
• 2.8 Key Market Highlights by End User
• 2.9 Key Market Highlights by Solutions
• 2.10 Key Market Highlights by Mode

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Antiparasitic
  • 4.1.2 Antibacterial
  • 4.1.3 Antiviral
  • 4.1.4 Antifungal
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Drugs
  • 4.2.2 Vaccines
  • 4.2.3 Diagnostics
  • 4.2.4 Therapeutic Devices
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Clinical Trials
  • 4.3.2 Consulting
  • 4.3.3 Regulatory Services
  • 4.3.4 Distribution Services
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Biotechnology
  • 4.4.2 Nanotechnology
  • 4.4.3 Genomics
  • 4.4.4 Proteomics
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Human Health
  • 4.5.2 Veterinary
  • 4.5.3 Research
  • 4.5.4 Public Health Initiatives
• 4.6 Market Size & Forecast by Form (2020-2035)
  • 4.6.1 Tablets
  • 4.6.2 Capsules
  • 4.6.3 Injectables
  • 4.6.4 Topicals
• 4.7 Market Size & Forecast by Deployment (2020-2035)
  • 4.7.1 Hospital Pharmacies
  • 4.7.2 Retail Pharmacies
  • 4.7.3 Online Pharmacies
  • 4.7.4 Research Laboratories
• 4.8 Market Size & Forecast by End User (2020-2035)
  • 4.8.1 Hospitals
  • 4.8.2 Clinics
  • 4.8.3 Research Institutes
  • 4.8.4 Government Organizations
  • 4.8.5 Non-Profit Organizations
• 4.9 Market Size & Forecast by Solutions (2020-2035)
  • 4.9.1 Disease Management
  • 4.9.2 Patient Monitoring
  • 4.9.3 Data Analytics
  • 4.9.4 Supply Chain Management
• 4.10 Market Size & Forecast by Mode (2020-2035)
  • 4.10.1 In-Person
  • 4.10.2 Remote
  • 4.10.3 Hybrid

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 Form
    • 5.2.1.7 Deployment
    • 5.2.1.8 End User
    • 5.2.1.9 Solutions
    • 5.2.1.10 Mode
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 Form
    • 5.2.2.7 Deployment
    • 5.2.2.8 End User
    • 5.2.2.9 Solutions
    • 5.2.2.10 Mode
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 Form
    • 5.2.3.7 Deployment
    • 5.2.3.8 End User
    • 5.2.3.9 Solutions
    • 5.2.3.10 Mode
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 Form
    • 5.3.1.7 Deployment
    • 5.3.1.8 End User
    • 5.3.1.9 Solutions
    • 5.3.1.10 Mode
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 Form
    • 5.3.2.7 Deployment
    • 5.3.2.8 End User
    • 5.3.2.9 Solutions
    • 5.3.2.10 Mode
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 Form
    • 5.3.3.7 Deployment
    • 5.3.3.8 End User
    • 5.3.3.9 Solutions
    • 5.3.3.10 Mode
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 Form
    • 5.4.1.7 Deployment
    • 5.4.1.8 End User
    • 5.4.1.9 Solutions
    • 5.4.1.10 Mode
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 Form
    • 5.4.2.7 Deployment
    • 5.4.2.8 End User
    • 5.4.2.9 Solutions
    • 5.4.2.10 Mode
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 Form
    • 5.4.3.7 Deployment
    • 5.4.3.8 End User
    • 5.4.3.9 Solutions
    • 5.4.3.10 Mode
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 Form
    • 5.4.4.7 Deployment
    • 5.4.4.8 End User
    • 5.4.4.9 Solutions
    • 5.4.4.10 Mode
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 Form
    • 5.4.5.7 Deployment
    • 5.4.5.8 End User
    • 5.4.5.9 Solutions
    • 5.4.5.10 Mode
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 Form
    • 5.4.6.7 Deployment
    • 5.4.6.8 End User
    • 5.4.6.9 Solutions
    • 5.4.6.10 Mode
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 Form
    • 5.4.7.7 Deployment
    • 5.4.7.8 End User
    • 5.4.7.9 Solutions
    • 5.4.7.10 Mode
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 Form
    • 5.5.1.7 Deployment
    • 5.5.1.8 End User
    • 5.5.1.9 Solutions
    • 5.5.1.10 Mode
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 Form
    • 5.5.2.7 Deployment
    • 5.5.2.8 End User
    • 5.5.2.9 Solutions
    • 5.5.2.10 Mode
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 Form
    • 5.5.3.7 Deployment
    • 5.5.3.8 End User
    • 5.5.3.9 Solutions
    • 5.5.3.10 Mode
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 Form
    • 5.5.4.7 Deployment
    • 5.5.4.8 End User
    • 5.5.4.9 Solutions
    • 5.5.4.10 Mode
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 Form
    • 5.5.5.7 Deployment
    • 5.5.5.8 End User
    • 5.5.5.9 Solutions
    • 5.5.5.10 Mode
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 Form
    • 5.5.6.7 Deployment
    • 5.5.6.8 End User
    • 5.5.6.9 Solutions
    • 5.5.6.10 Mode
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 Form
    • 5.6.1.7 Deployment
    • 5.6.1.8 End User
    • 5.6.1.9 Solutions
    • 5.6.1.10 Mode
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 Form
    • 5.6.2.7 Deployment
    • 5.6.2.8 End User
    • 5.6.2.9 Solutions
    • 5.6.2.10 Mode
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 Form
    • 5.6.3.7 Deployment
    • 5.6.3.8 End User
    • 5.6.3.9 Solutions
    • 5.6.3.10 Mode
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 Form
    • 5.6.4.7 Deployment
    • 5.6.4.8 End User
    • 5.6.4.9 Solutions
    • 5.6.4.10 Mode
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 Form
    • 5.6.5.7 Deployment
    • 5.6.5.8 End User
    • 5.6.5.9 Solutions
    • 5.6.5.10 Mode

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Eisai Co Ltd
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Sanofi Pasteur
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Gilead Sciences
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Boehringer Ingelheim
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Fujifilm Holdings Corporation
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Merck KGaA
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Johnson & Johnson
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Novartis AG
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Pfizer Inc
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 GlaxoSmithKline plc
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 AbbVie Inc
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Bayer AG
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Roche Holding AG
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 AstraZeneca
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Bristol-Myers Squibb
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Eli Lilly and Company
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Takeda Pharmaceutical Company
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Amgen Inc
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Biocon Limited
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Cipla Limited
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us